Literature DB >> 26645551

Current incidence and outcome of the acute respiratory distress syndrome.

Jesús Villar1, Jesús Blanco, Robert M Kacmarek.   

Abstract

PURPOSE OF REVIEW: This article discusses recently published articles reporting the incidence and outcome of patients with the acute respiratory distress syndrome (ARDS). This is a difficult task since there is a marked variability regarding the methodology of the few, large epidemiological, and observational studies on ARDS. RECENT
FINDINGS: The review will mainly focus on publications from the past 18 months. We have reviewed new epidemiological studies reporting population-based incidence of ARDS. Also, we have reviewed the data on survival reported in observational and randomized controlled trials, discussed how the current ARDS definition modifies the true incidence of ARDS, and briefly mentioned recent approaches that appear to improve ARDS outcome.
SUMMARY: On the basis of current evidence, it seems that the incidence and overall hospital mortality of ARDS has not changed substantially in the last decade. Independent of the definition used for identification of ARDS patients, reported population-based incidence of ARDS is an order of magnitude lower in Europe than in the USA. Current hospital mortality of combined moderate and severe ARDS reported in observational studies is greater than 40%.

Entities:  

Mesh:

Year:  2016        PMID: 26645551     DOI: 10.1097/MCC.0000000000000266

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  71 in total

Review 1.  Lung Repair and Regeneration in ARDS: Role of PECAM1 and Wnt Signaling.

Authors:  Jesús Villar; Haibo Zhang; Arthur S Slutsky
Journal:  Chest       Date:  2018-10-28       Impact factor: 9.410

2.  Pilot Feasibility Study of Therapeutic Hypothermia for Moderate to Severe Acute Respiratory Distress Syndrome.

Authors:  Donald F Slack; Douglas S Corwin; Nirav G Shah; Carl B Shanholtz; Avelino C Verceles; Giora Netzer; Kevin M Jones; Clayton H Brown; Michael L Terrin; Jeffrey D Hasday
Journal:  Crit Care Med       Date:  2017-07       Impact factor: 7.598

Review 3.  Postintensive Care Syndrome in Pediatric Critical Care Survivors: Therapeutic Options to Improve Outcomes After Acquired Brain Injury.

Authors:  Cydni N Williams; Mary E Hartman; Kristin P Guilliams; Rejean M Guerriero; Juan A Piantino; Christopher C Bosworth; Skyler S Leonard; Kathryn Bradbury; Amanda Wagner; Trevor A Hall
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.598

4.  The APPS: an outcome score for the acute respiratory distress syndrome.

Authors:  Jesús Villar; Robert M Kacmarek
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

5.  From Berlin to Kigali: the sobering journey of acute respiratory distress syndrome.

Authors:  Thomas Bein
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

6.  "Open the lung and keep it open": a homogeneously ventilated lung is a 'healthy lung'.

Authors:  Joshua Satalin; Penny Andrews; Louis A Gatto; Nader M Habashi; Gary F Nieman
Journal:  Ann Transl Med       Date:  2016-04

7.  Mortality and pulmonary mechanics in relation to respiratory system and transpulmonary driving pressures in ARDS.

Authors:  Elias Baedorf Kassis; Stephen H Loring; Daniel Talmor
Journal:  Intensive Care Med       Date:  2016-06-18       Impact factor: 17.440

8.  The Kigali modification of the berlin definition: a new epidemiological tool for ARDS?

Authors:  Chiara Lazzeri; Adriano Peris
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 9.  Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.

Authors:  M Isabel García-Laorden; José A Lorente; Carlos Flores; Arthur S Slutsky; Jesús Villar
Journal:  Ann Transl Med       Date:  2017-07

10.  Should the ART trial change our practice?

Authors:  Jesús Villar; Fernando Suárez-Sipmann; Robert M Kacmarek
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.